Edition:
United States

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

79.35USD
19 Jul 2018
Change (% chg)

-- (--)
Prev Close
$79.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
193,083
52-wk High
$85.05
52-wk Low
$17.60

Chart for

About

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $2,516.56
Shares Outstanding(Mil.): 31.94
Dividend: --
Yield (%): --

Financials

  RGNX.OQ Industry Sector
P/E (TTM): 56.77 212.74 32.86
EPS (TTM): 1.39 -- --
ROI: 20.55 -3.73 13.13
ROE: 20.72 -5.79 15.07

BRIEF-Regenxbio Receives $100 Mln Accelerated License Payment

* REGENXBIO RECEIVES $100 MILLION ACCELERATED LICENSE PAYMENT DUE TO ACQUISITION OF AVEXIS BY NOVARTIS

Jun 11 2018

BRIEF-Regenxbio Reports Q1 Earnings Per Share $3.04

* REGENXBIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

May 08 2018

BRIEF-Regenxbio Inc Q4 Loss Per Share ‍$0.51​

* REGENXBIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

Mar 06 2018

BRIEF-Regenxbio Enters Strategic Partnership With Fujifilm Diosynth Biotechnologies

* REGENXBIO ENHANCES GENE THERAPY MANUFACTURING CAPABILITIES BY ENTERING INTO STRATEGIC PARTNERSHIP WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES

Jan 23 2018

Earnings vs. Estimates